37105-10-5

Basic information

• Product Name: 6-chloro-5-Methylpyridine-3-sulfonyl chloride
• Synonyms: 6-chloro-5-Methylpyridine-3-sulfonyl chloride;6-Chloro-5-methyl-pyridine-3-sulphonylchloride
• CAS NO: 37105-10-5
• Molecular Formula: C₆H₅Cl₂NO₂S
• Molecular Weight: 226.0804
• EINECS: -0
• Mol File: 37105-10-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 330.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.532±0.06 g/cm3(Predicted)
• PKA: -4.68±0.10(Predicted)
• CAS DataBase Reference: 6-chloro-5-Methylpyridine-3-sulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-5-Methylpyridine-3-sulfonyl chloride(37105-10-5)
• EPA Substance Registry System: 6-chloro-5-Methylpyridine-3-sulfonyl chloride(37105-10-5)

Safety Data

• Hazardous Substances Data: 37105-10-5(Hazardous Substances Data)

Upstream product

• 22280-56-4 2-chloro-3-methyl-5-nitropyridine 
• 38186-82-2 6-chloro-5-methylpyridin-3-amine 

Downstream Products

• 881677-00-5 1-[(6-chloro-5-methylpyridin-3-yl)sulfonyl]-5-phenyl-1H-pyrrole-3-carbaldehyde 

Relevant articles and documents

METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS

Provided herein are compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

PROTON PUMP INHIBITORS

A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.